Drugs / RVP-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05413668 | May → Jul 2022 | — | Reveal Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06322342 | Aug 2024 → Dec 2025 | acoustic neuroma, benign neoplasm of brain, meningioma, metastatic malignant neoplasm in the brain +4 | Reveal Pharmaceuticals Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RVP-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06322342 ↗ |
| Known as | Mn-PyC3A | “which is developing Mn-PyC3A (RVP-001).” PMID 38038701 ↗ Dec 2023 |
| Modality | Diagnostic / imaging agent | “Magnetic Resonance Imaging (MRI) Contrast Agent” NCT05413668 ↗ |
| Route | Intravenous | “Intravenous administration of RVP-001” NCT05413668 ↗ |